Unveiling Precision Medicine: Transforming Healthcare Through Personalized Approaches

Trishita Deb
Trishita Deb

Updated · May 28, 2024


At Market.us Media, we strive to bring you the most accurate and up-to-date information by utilizing a variety of resources, including paid and free sources, primary research, and phone interviews. Learn more.
Advertiser Disclosure

At Market.us Media, we strive to bring you the most accurate and up-to-date information by utilizing a variety of resources, including paid and free sources, primary research, and phone interviews. Our data is available to the public free of charge, and we encourage you to use it to inform your personal or business decisions. If you choose to republish our data on your own website, we simply ask that you provide a proper citation or link back to the respective page on Market.us Media. We appreciate your support and look forward to continuing to provide valuable insights for our audience.


The Global Precision Medicine Market size is projected to experience significant growth, with its valuation expected to reach approximately USD 254 billion by 2032. This represents a substantial increase from USD 93.5 billion in 2023, marking a Compound Annual Growth Rate (CAGR) of 12.1% during the forecast period from 2022 to 2032. This remarkable growth can be attributed to several factors.

Precision medicine involves analyzing the genes and proteins present in a patient’s body to design personalized treatment drugs for specific diseases. Key discoveries in the field, such as single nucleotide polymorphisms and microarray/biochips, are expected to drive significant market growth in the coming years. Research on the human genome is crucial for the future of precision medicine, offering the potential to revolutionize medical treatment by understanding patients’ genetics, molecular profiles, and clinical characteristics to develop effective treatments.

Several factors are expected to increase the demand for precision medicine. The rising prevalence of cancer is anticipated to boost the need for personalized therapeutics and diagnostics, positively influencing market growth. Additionally, advancements in computational tools and genetic technology enable the examination of genetic changes that lead to cancer, further supporting the growth of precision medicine, particularly in cancer treatment.

However, the high cost of precision medicine and challenges with reimbursement policies are potential hindrances to market growth. The use of advanced computational techniques and high-end calculation methodologies contributes to the overall expense of precision medicine. Despite these challenges, ongoing innovations in genetic technology and computational tools are expected to continue fueling the growth of precision medicine, especially in the context of cancer diagnostics and treatment.

To learn more about this report – request a sample report PDF

Key Takeaways

  • Market size in 2023: USD 93.5 billion
  • Forecasted market size in 2032: USD 254 billion
  • Compound Annual Growth Rate (CAGR) from 2023 to 2032: 12.1%
  • Revenue share of North America in 2022: Over 40%
  • Global Precision Medicine market size in 2022: USD 83.4 billion
  • Biopharmaceutical industry spending on R&D: USD 179 billion
  • Precision Medicine market share dominated by North America in 2022: Above 40%
  • Number of cancer-related deaths reported by the American Cancer Society in the US in 2020: Approximately 606,520
  • Number of new disease cases reported by the American Cancer Society in the US in 2020: 1.8 million

Precision Medicine Statistics

  • Revenue of North American Precision Medicine Market (2022): USD 33.4 billion
  • CAGR of Asia Pacific Precision Medicine Market (forecast period): Not specified
  • Cancer-related deaths in the US (2020): Approximately 606,520
  • New cancer cases in the US (2020): Approximately 1.8 million
  • Annual rate of new cancer cases per 100,000 men and women: 442.4
  • Annual cancer-related deaths per 100,000 men and women: 158.3
  • Expected cancer cases in adults and children (0-19 years old): 16,850
  • Expected cancer-related deaths in adults and children (0-19 years old): 1,730
  • Percentage ofbreast cancer patients experiencing treatment delay (July 2020): 31.7%
  • Percentage of individuals in the US reporting delay in cancer screening due to COVID-19 (2020): 22%
  • Percentage of individuals in the US reporting delay in cancer treatment due to COVID-19 (2020): 9.3%
  • Success rates of drug discovery and development:
    • Phase I: Approximately 75%
    • Phase II: Approximately 50%
    • Phase III: Approximately 59%
  • New drug application phase: Approximately 88%
  • Disease control rate with targeted treatment based on F1CDx testing: 41.1%
  • Partial response rate with targeted treatment based on F1CDx testing: 23.5%
  • Disease rate with targeted treatment based on F1CDx testing: 17.6%
  • Revenue of Precision Oncology Market (2022): USD 81.37 billion
  • Projected Revenue of Precision Oncology Market (2032): USD 202.5 billion
  • Revenue of the Prescription Drugs segment in the UK (expected by end of 2023): USD 39.99 billion
  • CAGR of the Prescription Drugs segment in the UK (2023-2027): 4.97%
  • Revenue of healthcare in China (expected by end of 2023): USD 19.94 billion
  • CAGR of the medical technology market in China (2023-2027): 7.39%
  • Total non-oncology precision medicine market revenue (2019): USD 41.1 billion
  • Projected revenue of the total non-oncology precision medicine market (2032): USD 129.9 billion
  • Revenue of the Global DNA Sequencing Market (2022): USD 10.1 billion
  • Projected revenue of the Global DNA Sequencing Market (2032): USD 40.5 billion
  • Revenue of the DNA Sequencing Market in North America (2022): USD 4.4 billion

Emerging Trends

  • Advancements in Genomic Sequencing: Next Generation Sequencing (NGS) tests are rapidly advancing, enabling the identification of large sections of the genome. These tests are crucial for diagnosing and treating diseases with a genetic basis.
  • Integration with Artificial Intelligence (AI): AI is increasingly used to analyze large datasets from precision medicine, helping identify patterns and predict disease outcomes, thus personalizing treatment plans.
  • Expansion of the All of Us Research Program: This NIH initiative has enrolled over 750,000 participants, aiming for at least 1 million. The program focuses on gathering diverse health data to ensure inclusivity in biomedical research.
  • Increased Focus on Diversity: More than 80% of the participants in the All of Us program are from historically underrepresented groups, with over 50% from racial and ethnic minorities. This diversity is essential for developing treatments that are effective across different populations.
  • Policy and Regulatory Support: The FDA has streamlined the approval process for NGS-based tests and other precision medicine tools, ensuring that innovative diagnostic methods can be brought to market more quickly.
  • Public-Private Collaborations: Initiatives like Sync for Science and Sync for Genes focus on standardizing the sharing of electronic health record data and genomic information, respectively, to enhance research and clinical applications.
  • Use of Wearable Technology: Wearable devices are becoming integral to precision medicine by continuously collecting health data, which helps in monitoring and managing chronic conditions.
  • Integration of Environmental and Lifestyle Data: Precision medicine increasingly incorporates data on patients’ environments and lifestyles to provide more comprehensive and effective treatment plans.
  • Enhanced Data Infrastructure: Significant investments are being made to improve the data infrastructure necessary for precision medicine, including the development of secure and interoperable health IT systems.
  • Ethical and Privacy Considerations: As precision medicine relies heavily on genetic and health data, there is a strong focus on developing policies and standards to protect patient privacy and data security.
  • Clinical Trials and Personalized Therapies: A growing number of clinical trials now include precision medicine approaches, using genetic profiling to tailor treatments and improve outcomes.
  • Economic Impact: The Precision Medicine Initiative (PMI), launched in 2015, continues to drive significant investments and innovations in personalized healthcare, aiming to improve treatment efficacy and reduce healthcare costs.
  • Real-World Evidence (RWE): The use of real-world evidence from health records, patient registries, and other data sources is increasing, providing insights into the effectiveness of precision medicine treatments in diverse populations.
  • Focus on Rare Diseases: Precision medicine is making significant strides in the diagnosis and treatment of rare diseases by identifying specific genetic mutations and developing targeted therapies.

Use Cases

  • Cancer Treatment: Precision medicine is revolutionizing oncology by tailoring treatments based on the genetic profiles of individual tumors. This approach allows for more effective therapies and reduces adverse effects by targeting specific mutations within cancer cells​​.
  • Cardiovascular Diseases: Precision medicine helps in identifying genetic predispositions to cardiovascular diseases. By analyzing patients’ genetic information, doctors can recommend personalized prevention strategies and treatments​.
  • Pharmacogenomics: This field studies how genes affect a person’s response to drugs. Precision medicine uses pharmacogenomics to develop customized medication plans, improving efficacy and minimizing side effects​.
  • Rare Diseases: Precision medicine is crucial for diagnosing and treating rare diseases, which often have a genetic basis. By identifying specific genetic mutations, targeted therapies can be developed, providing new hope for patients with rare conditions​​.
  • Neurological Disorders: Genetic testing and precision medicine approaches are used to better understand and treat neurological disorders like Alzheimer’s disease and Parkinson’s disease, by identifying genetic markers that influence disease progression and treatment response​​.
  • Diabetes Management: Precision medicine helps in managing diabetes by tailoring treatment plans based on genetic and lifestyle factors, improving blood sugar control and reducing complications​​.
  • Immunotherapy: Precision medicine plays a vital role in immunotherapy for cancer treatment. By analyzing the genetic makeup of both the patient and the tumor, therapies can be designed to boost the immune system’s ability to fight cancer cells​.
  • Genetic Counseling: Precision medicine provides genetic counseling to individuals and families at risk for genetic disorders, offering insights into potential health risks and helping in making informed decisions about health management.
  • Prenatal Screening: Precision medicine enables advanced prenatal screening tests to detect genetic abnormalities in fetuses, allowing for early interventions and informed decision-making for expecting parents.
  • Infectious Diseases: By understanding the genetic makeup of pathogens and the host’s immune response, precision medicine aids in developing targeted vaccines and treatments for infectious diseases​​.


In conclusion, the Precision Medicine Market is poised for substantial growth, driven by advancements in genomic sequencing, integration with artificial intelligence, and policy support for innovative diagnostic methods. Real-world evidence is increasingly shaping treatment strategies, particularly in oncology, cardiovascular diseases, and rare conditions. Moreover, precision medicine’s role in pharmacogenomics, neurology, diabetes management, immunotherapy, genetic counseling, prenatal screening, and infectious diseases underscores its broad impact across various healthcare domains. As the market expands, ethical considerations and data security remain paramount. Overall, precision medicine offers personalized and effective healthcare solutions, promising significant advancements in treatment efficacy and patient outcomes.

Trishita Deb

Trishita Deb

Trishita has more than 7 years of experience in market research and consulting industry. She has worked in various domains including healthcare, consumer goods, and materials. Her expertise lies majorly in healthcare and has worked on more than 400 healthcare reports throughout her career.